{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-058085","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.423293+00:00","generated_at":"2026-06-15T07:12:13.757855+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Pharma Q1 net loss $4.0M; initiates Phase 1b for NXP800 in ovarian cancer","bullets":["Cash $15.5M as of March 31, 2023 vs $20.0M at Dec 31, 2022; net loss $4.0M (Q1 2023) vs $2.9M (Q1 2022).","Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer initiated; multicenter trial with GOG Foundation and ENGOT.","IND for NXP900 pending; first-in-human trial expected shortly after IND becomes effective.","Mayo Clinic investigators presented in-vivo PDX data at AACR showing NXP800 potential in cholangiocarcinoma.","Company expects cash into H2 2024; R&D expenses $2.4M (up $0.6M YoY), G&A $1.7M (up $0.6M YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-058085","json":"https://secwatch.observer/filing/0001104659-23-058085.json","markdown":"https://secwatch.observer/filing/0001104659-23-058085.md","text":"https://secwatch.observer/filing/0001104659-23-058085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/0001104659-23-058085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/tm2315012d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:12:13.757855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9bf5020fbafe14f0d3bca23828748530fc033d4","claim":"Nuvectis Pharma, Inc. reported first quarter 2023 results: net income Net loss was $4.0 million for the three months ended March 31, 2023.","evidence_excerpt":"Net loss was $4.0 million for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923058085/0001104659-23-058085-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Net income","value":"Net loss was $4.0 million for the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}